2026 BCI funding on pace for $2B annual total — $653M raised January through April
Summary
From January through April 2026, $653 million in new capital was raised by implanted BCI companies alone, according to commercial analysis by Neurotech Futures. Led by Merge Labs ($252M) and Science Corporation ($230M), the H1 2026 total is already at 45% of last year's full-year $1.46B in BCI specifically. At this pace, 2026 BCI funding will reach approximately $2 billion — making it the second consecutive year of major acceleration. The analysis notes Boston Scientific's $14.5B Penumbra acquisition as a strategic bet on neural access by a DBS company, even if not strictly BCI.
Why it matters
BCI-specific funding reaching $2B annually would cement brain-computer interfaces as a mainstream investment category comparable to gene therapy ($3.5B in 2025) and cell therapy ($4.2B in 2025). The 45% mark by April suggests funding is broadly distributed across the year rather than dependent on a single Q1 mega-round — a structural maturity signal for the category.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial